A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis (NCT07112378)
A Randomized Study Evaluating 2 Dose Regimens of Dupilumab in Children ≥6 Months of Age Weighing ≥5 to <15 kg With Active Eosinophilic Esophagitis
🩺 Plain-English Summary (8th-Grade Level)
This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment. The aim of the study is to see how safe, tolerable, and effective the study drug is when given for 24 weeks to children with active EoE. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Who can join: Review the eligibility criteria below.
Location: Phoenix Childrens Hospital — Phoenix, Arizona
Age range: 6 Months to 6 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Phoenix Childrens Hospital — Phoenix, Arizona
- University of California San Francisco (UCSF) — San Francisco, California
- Children's Hospital Colorado — Aurora, Colorado
- GI Care for Kids LLC — Atlanta, Georgia
- Massachusetts General Hospital — Boston, Massachusetts
- Weill Cornell Medicine — New York, New York
- University of North Carolina, Bioinformatics Building — Chapel Hill, North Carolina
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Medical University of South Carolina — Charleston, South Carolina
- Cook Children's Medical Center — Fort Worth, Texas
- University of Virginia — Charlottesville, Virginia
- Seattle Children's Hospital — Seattle, Washington
- Medical College of Wisconsin, Children's Hospital of Wisconsin — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (844) 734-6643
Email: clinicaltrials@regeneron.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Eosinophilic Esophagitis (EoE)
- A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care — Phoenix, Arizona
- Surface EMG Testing on Swallowing in EoE Patients — Rochester, Minnesota
- A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis — Dothan, Alabama
- Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy — Philadelphia, Pennsylvania
- Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE) — La Jolla, California
Explore by condition: All Eosinophilic Esophagitis (EoE) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.